Trial Profile
Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Tinzaparin sodium (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms PREDICARE
- Sponsors LEO Pharma
- 12 Dec 2023 Results (n=1413) a meta-analysis from this and NCT02898051, NCT01164046 and NCT01130025 studies on individual patient level data to report the rate of rVTE and MB by 6 months according to site of cancer from prospective studies involving CAT patients on tinzaparin, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Apr 2021 Results published in the Thrombosis and Haemostasis
- 31 May 2020 Primary endpoint has not been met. (Venous thromboembolism recurrence), as reported in an abstract presented at the 56th Annual Meeting of the American Society of Clinical Oncology